Oleh :
Evan Dionesia Gravianto
G4A018018
Pembimbing :
dr. Lopo Triyanto, Sp.B-(K) Onk
2019
LEMBAR PENGESAHAN
Disusun oleh:
Evan Dionesia Gravianto
G4A018018
Telah disetujui
Mengetahui
Pembimbing :
A. Gambaran Umum
Terapi pada kanker payudara harus didahului diagnosis kerja yang definitif
(termasuk penetapan stadium). Diagnosis dan terapi pada kanker payudara harus
dilakukan dengan pendekatan komprehensif; artinya seluruh diagnosis yang
sudah ditegakkan harus diterapi (diagnosis utama, sekunder dan komplikasi).
Terapi utama pada solid tumor (kanker padat) adalah pembedahan, sedangkan
terapi non-bedah terdiri dari terapi radiasi, kemoterapi, terapi hormon, terapi
target, imunoterapi dan terapi komplementer. Terapi pada kanker payudara
ditentukan oleh stadium. Setiap tujuan terapi, komplikasi dan efek samping dari
tindakan yang harus dikomunikasikan kepada pasien dan keluarga.1,2 Berbagai
pandangan tentang terapi kanker payudara dapat dibagi atas:1,2,3
1. Menurut Tujuannya
- Kuratif, berharap terapi yang diberikan akan menghasilkan “kesembuhan”
dan dengan demikian akan meningkatkan periode bebas penyakit dan
kesintasan.
- Paliatif dan simtomatik, terapi yang diberikan akan memperbaiki keadaan
umum penderita dengan sedikit harapan memperpanjang kesintasan.
2. Menurut Jenis
- Primer, yaitu memberikan terapi dengan fokus pada kanker sebagai
penyakit primernya (dapat berupa terapi utama, adjuvan/neoadjuvan).
- Sekunder, memberikan terapi atas penyakit sekunder/ komorbid (penyakit
komorbid/sekunder adalah penyakit lain di luar penyakit primer atau
kanker tersebut yang mungkin akan dapat mempengaruhi prognosis atau
mempengaruhi terlaksananya terapi primer).
- Terapi komplikasi, yaitu terapi khusus terhadap komplikasi yang terjadi
akibat penyakit primernya (kanker). Misal: fiksasi interna pada fraktur
tulang panjang akibat metastasis, aspirasi cairan pleura pada efusi pleura
metastasis.
3. Menurut Modalitas Terapi1,2
- Lokal dan regional: operasi, terapi radiasi
- Sistemik: terapi hormon, kemoterapi, terapi target, imunoterapi dan
komplementer
4. Menurut Cara / Strategi Pemberian Terapi
- Berurutan (sequential), pemberian berbagai modalitas terapi secara
bergantian atau berurutan
- Bersamaan (combined), pemberian berbagai modalitas terapi secara
bersamaan.
1. Burstein HJ, Harris JF, Morrow M. Malignant Tumor of the Breast. In. Devita
VT, Hellman S, Rosenberg SA. Cancer Principles & Practice of Oncology.
Ed.8. Philadelphia. Lippincott William & Wilkins. 2008. 1620-32.
2. Kwon DS, Kelly CM, CHING CD. Invasive Breast Cancer. In. Feig BW, Ching
CD. The MD Anderson Surgical Surgical Oncology Handbook. 5th edition.
Philadelphia. Lippincott Wiliam and Wilkins; 2012.P.43- 59.
3. Veronesi Umberto, C Natale, L Mariani, et.al. Twenty Year Follow Up of a
Randomized Study Comparing Breast-Conserving Surgery with Radical
Mastectomy For Early Breast Cancer. MAssaschusets Medical Society, October
17, 2002: 347.
4. Fisher B, Stewart A, Bryant J, et al. Twenty Year Follow-Up a Randomized Trial
Comparing Total Mastectomy, Lumpectomy, and Lumpectomy Plus Irradiation
For The Treatment of Invasive Breast Cancer. New Eng J of Med. 2002 Oct;
347(16).
5. Litiere S, Werustky G, Fentiman Ian, et.al. Breast Conseving Therapy versus
Mastectomy for Stage I-II Breast Cancer: 20 Year Follow-Up of the EORTC
10801 phase 3 Randomised Trial. Lancet Oncol. 2012. P.412-419.
6. Love, Richard R., Nguyen Van Dinh, Tran Tu Quy, et.al. Survival After Adjuvant
Oophorectomy and Tamoxifen in Operable Breast Cancer In Premenopausal
Woman. J of Clin Onc, 2008;26(2).
7. Meimarakis G, Ruttinger D, Stemmler J, Crispin A, Weidenhagen R, Angele M,
et.al. Prolonged overall survival after pulonary metastasisctomy in patients with
breast cancer. Ann Thorac Surg. 2013 Apr; 95 (4):1170-80
8. Ehrl D, Rothaug K, Hempel D, Rau HG. Importance of liver resection in case of
hepatic breast metastasis. Hepatogastroenterology. 2013 Nov-Dec;
60(128):2026-33.
9. Kwon DS, Kelly CM, CHING CD. Invasive Breast Cancer. In. Feig BW, Ching
CD. The MD Anderson Surgical Surgical Oncology Handbook. 5th edition.
Philadelphia. Lippincott Wiliam and Wilkins. 2012.P:59-71.
10. Senkus E, Kyriakides S, Liorca P, Portmans P, Thompson A, Zackrisson S,
Cordoso F. Primary breast cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and Follow up. Ann of Onc. 2211-4. 0. 8-12.
11. Goldirsch A, Winer EP, Coates AS, Gelber RD, Gebhart MP, Thurlimann B,
Senn HJ. Personalizing the treatment of women with early breast cancer:
highlighs of the St Gallen International Expert Consensus on the Primary
Therapy on Early Breast Cancer 2013. Ann of Onc. 2013. 24. 2206-23
12. Hassan MSU, Ansari J, Spooner D, Hussain SA. Chemotherapy for Breast
Cancer. Oncolgy Reports. Birmingham. 2010. 24. 1121-31.
13. NCCN Clinical Practice in Oncology. Breast Cancer. Version 3. 2014.
14. Hofstatter EW, Chung GG, Harris LN. Malignant Tumor of the Breast. In;
Devita VT, Lawrence TS. Rosenberg SA Cancer Principles & Practice of
Oncology. 9th.Philadelphia. 2011.P:1435.
15. Casciato Dennis A. Penyunting. Manual of Clinical Oncology. Lippincot
William & Wilkin. Philadelphia. 2004.
16. Burstein, Harold J. Ann Alexis Prestrud, et.al. American Society of Clinical
Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy
for Women with Hormone Receptor Positif Breast Cancer. J of Clin Oncol.
2010(28):23.
17. Kwon DS, Kelly CM, Cing CD. Invasive Breast Cancer in Feig BS, Ching CD.
Editor. The MD Anderson Surgical Oncology HandBook. Philadelphia.
Lippincot Willian and Wilkin. 2012.P:66-7.
18. Cruzick J, Sestidak I, Baum M, Effect of Anastrozole and Tamoxifen as a Adjuvat
treatment for Early Breast Cancer 10 years Analysis ATAC trial. Lancet
Oncology. 2010. 11. 1135-41.
19. Bedognetti D, Sertoli RM, Pronzato P etal, Concurrent vs Sequential Adjuvant
Chemotherapy and Hormone Therapy in Breast cancer : A Multicentre
Randomized Phase III Trial. JNCI. 2011(103):20: 1529-1539.
20. Philipps AL, Ichinawa L, Buist DSM. Defining Menopousal Status: Comparison
of Multiple Aproaches and Their Effect of Breast Cancer Rate. Maturitas. 2010.
67(1). 60-6.
21. Troisi R, Hatch EE, Ernstoff LT. et al. Cancer Risk in Women Prenatal Exposed
to Diethylstilbestrol. Int J Canc 2007(121):2:356-60
22. Uray IP, Brown PA.Chemoprevention of Hormon Receptor Negatif Breast
Cancer:New Aproches Needed. Recent Research Cancer Res. 2011.188. 147-62.
23. Perez E. Safety Profiles of Tamoxifen and The Aromatase Inhibitors in Adjuvant
Therapy of Hormone Responsive Early Breast Cancer. Ann Oncol.
2007;18:8:viii26-35
24. Fang,Lei, Zeinab Barekari, Bei Zhang, Zhiyong Liu, Xiaoyan Zhong. Targeted
Therapy in Breast Cancer: What‘s New? European J of Med Sci. 2011.
25. Chu E, Devita VT. Phyisicians Cancer Chemotherapy Drug Manual.
Burlington. Jones and Barlett Learning. 2012.370-2.
26. Azambuja J, Holmes AP, Picart-Gebhart, et al. Lapatinib with trastuzumab for
HER2-positif early breast cancer (NeoALTTO): survival outcomes of a
randomised, open-label, multicentre, phase 3 trial and their association with
pathological complete response. Lancet Oncol. 2014.
27. Hope S. Rugo. Bevacizumab in the Treatment of Breast Cancer: Rationale and
Current Data. The Oncologists. San Francisco, 2004
28. Burstein HJ, Harris JF, Morrow M. Malignant Tumor of the Breast. In. Devita
VT, Hellman S, Rosenberg SA. Cancer Principles & Practice of Oncology.
Ed.9. Philadelphia. Lippincott William & Wilkins. 2011. 1443
29. Baselga Jose, Campone Mario, Piccart Martine, Burris HA, Rugo HH, Sahmoud
Tarek, Noguchi Shinzaburo, et al. Everolimus in Postmenopausal Hormone-
Receptor–Positif Advanced Breast Cancer. The New England Journal of
Medicine. 2012; 366:520-529
30. Lisa M. DiGianni, Judy E. Garber, Eric P. Winer. Complementary and
Alternative Medicine Use Among Women With Breast Cancer. J Clinical
Oncology.2002; 20: 34s-38s
31. B. Gerber, C. Scholz, T. Reimer, V. Briese, W. Janni. Complementary and
Alternative Therapeutic Approaches in Patients with Early Breast Cancer:A
Systematic Review. Breast Cancer Research and Treatment.2006(95);3:199-209
32. Nahleh Z, Tabbara IA. Complementary and Alternative Medicine in Breast
Cancer Patients. Palliat Support Care. 2003 Sep;1(3):267-73.
33. AJCC: Breast. In: Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging
Manual. 7th ed. New York. Springer, 2010.P:347-76
34. National Cancer Institute. Lymphedema. 2014 March 18. [cited 2014 July 11]
Available from: http://www.cancer.gov/cancertopics/pdq/ supportivecare/
lymphedema/healthprofessional/page2.
35. Golshan M. Mastectomy in Harris JR, Morrow M, Lippman MC, Osborne CK.
Disease of the breast 4th ed.P:501-6
36. Gennari A, Sormani MP, Prozanto P et al, HER2 Status and Efficacy of Adjuvant
Anthracyclin in Early Breast Cancer:A pooled Analysis of Randomized Trials. J
Natl Cancer Inst 2008;100: 14-20.
37. Romera, J.Lao, T.J. Puertolas Hernandezet.al. Update On Adjuvant Hormon
Treatment of Early Breast Cancer. Springer Health Care, 2011(28):6:p.1-18.
38. Dahabreh, Issa J., Helen Linardou, Fotios Siannis, George Fountzilas, Samuel
Murray. Transtuzumab in the Adjuvant treatment of Early-Stage Breast Cancer:
A Systematic Review and Meta-Analysis of Ramdomized Controlled Trials. The
Oncologist 2008(13):620-630.
39. Harry D. Bear. Et al. The Effect on Tumor Response of Adding Sequential
Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide:
Preliminary Results From National Surgical Adjuvant Breast and Bowel Project
Protocol B-27.J Clin Oncol 21:4165-4174.
40. Goldhirsch A., et al. strategies for subtypes-dealing with the diversity of breast
cancer:highlights of the St gallen international expert concensus on the primary
therapy of early breast cancer 2011.Ann Oncol.2011:doi.10.1093/
annonc/mdr304
41. Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast
cancer:a surgical perspective. Eur J of Cancer.2002(38):2214-2221
42. Lee, Marie Catherine, Lisa A. Newman. Management of Patients with Lokally
Advanced Breast Cancer. Surgical Clinics of North AmericaVol. 87 (2007)
p.379-398.
43. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on
the outcome of women with operable breast cancer. J Clin Oncol 1998(16):2672-
2685,
44. Cardoso F.et al. locally recurrent or metastatic breast cancer: ESMO Clinical
practice guidelines for diagnostis, treatment and follow-up. Ann
Oncol.2011(6):25-30